Among the few inhibitors targeting the SH2 domain of STAT3 and interacting with STAT5, OPB-31121 has shown anti-tumor activity in leukemia, with ongoing phase I/II clinical trials assessing efficacy against solid tumors and hematopoietic cancers (195). The gene discussed is STAT3; the disease is neoplasm.